WatchGov

119th Congress

H.R. 2821

FDA Modernization Act 3.0

  1. Introduced
  2. In committee
  3. Passed House
  4. Passed Senate
  5. To President
  6. Became law
Sponsor
Earl L. "Buddy" Carter(R-GA)
Introduced
Apr 10, 2025
Policy area
Health
Committees
House Committee on Energy and Commerce
Official text
Engrossed in House · Congress.gov page

Cosponsors (41)

Original cosponsors (5)

Added later (36)

Summary

Summary by the Congressional Research Service· describes the “Introduced in House” version

FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

Roll-call votes

No recorded votes on this bill.

Actions